scholarly journals SUPPRESSION OF ADVANCED GLYCATION AND LIPOXIDATION END PRODUCTS BY ANGIOTENSIN II TYPE-1 RECEPTOR BLOCKER CANDESARTAN IN TYPE 2 DIABETIC PATIENTS WITH ESSENTIAL HYPERTENSION

2013 ◽  
Vol 59 (2) ◽  
pp. 69-75 ◽  
Author(s):  
YOSHIAKI ONO ◽  
KENJI MIZUNO ◽  
MICHIHIKO TAKAHASHI ◽  
YUKIO MIURA ◽  
TSUYOSHI WATANABE
2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Anna Lados-Krupa ◽  
Malgorzata Konieczynska ◽  
Artur Chmiel ◽  
Anetta Undas

Aims. We sought to investigate whether enhanced oxidation contributes to unfavorable fibrin clot properties in patients with diabetes.Methods. We assessed plasma fibrin clot permeation (Ks, a measure of the pore size in fibrin networks) and clot lysis time induced by recombinant tissue plasminogen activator (CLT) in 163 consecutive type 2 diabetic patients (92 men and 71 women) aged 65 ± 8.8 years with a mean glycated hemoglobin (HbA1c) of 6.8%. We also measured oxidative stress markers, including nitrotyrosine, the soluble form of receptor for advanced glycation end products (sRAGE), 8-iso-prostaglandin F2α(8-iso-PGF2α), oxidized low-density lipoprotein (oxLDL), and advanced glycation end products (AGE).Results. There were inverse correlations betweenKsand nitrotyrosine, sRAGE, 8-iso-PGF2α, and oxLDL. CLT showed a positive correlation with oxLDL and nitrotyrosine but not with other oxidation markers. All these associations remained significant forKsafter adjustment for fibrinogen, disease duration, and HbA1c (allP<0.05), while oxLDL was the only independent predictor of CLT.Conclusions. Our study shows that enhanced oxidative stress adversely affects plasma fibrin clot properties in type 2 diabetic patients, regardless of disease duration and glycemia control.


Sign in / Sign up

Export Citation Format

Share Document